

Jubilant Biosys (BVI) Limited
Balance Sheet as at 31 March 2017

	Notes No.	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
		USD	(INR'000)	USD	(INR'000)	USD	(INR'000)
ASSETS							
Financial assets							
Non-current Investments	1	1,371,501	88,942	1,371,501	90,862	1,371,501	85,719
Total non-current assets		1,371,501	88,942	1,371,501	90,862	1,371,501	85,719
Current assets							
Cash And cash equivalents	2	1,306	85	1,371	91	1,371	86
Other current assets	3	3,096	201	1,623	107	321	20
Total Current assets		4,402	286	2,994	198	1,692	106
Total Assets		1,375,903	89,228	1,374,495	91,060	1,373,193	85,825
EQUITY AND LIABILITIES							
Equity							
Equity share capital	4	1,397,501	69,846	1,397,501	69,846	1,397,501	69,846
Other equity	5	(34,823)	18,524	(31,293)	20,665	(27,134)	15,801
Total equity		1,362,678	88,370	1,366,208	90,511	1,370,367	85,648
Liabilities							
Current liabilities							
Financial liabilities							
Trade payables	6	13,224	858	8,287	549	2,826	177
Total current liabilities		13,224	858	8,287	549	2,826	177
Total Equity and Liabilities		1,375,903	89,228	1,374,495	91,060	1,373,193	85,825

Prakash C Bisht
CFO (LSI) & Senior VP (Group Accounts)
Place: Noida
Date: 23 May, 2017

Jubilant Biosys (BVI) Limited
Statement of Profit and Loss for the year ended 31 March 2017

	Notes No.	For the year ended 31 March 2017		For the year ended 31 March 2016	
		USD	(INR'000)	USD	(INR'000)
EXPENSES					
Other expenses	7	3,529	237	4,160	271
Total expenses		3,529	237	4,160	271
(Loss) for the Year		(3,529)	(237)	(4,160)	(271)
Items that will be reclassified to profit or loss					
Exchange difference on translation of foreign operations		-	(1,904)	-	22,363
Total other comprehensive Income , net of tax		-	(1,904)	-	22,363
Total comprehensive income for the year		(3,529)	(2,141)	(4,160)	22,092
Profit attributable to :					
Owners of the company		(3,529)	(237)	(4,160)	(271)
Non-controlling Interest		(3,529)	(237)	(4,160)	(271)
Total comprehensive Income attribute to:					
Owners of the company		(3,529)	(2,141)	(4,160)	22,092
Non-controlling Interest		(3,529)	(2,141)	(4,160)	22,092

Prakash C Bisht
CFO (LSI) & Senior VP (Group Accounts)
Place: Noida
Date: 23 May, 2017

Jubilant Biosys (BVI) Limited
Cash flow statement for the Year ended on 31 March 2017

Particulars	For the year ended on 31 March 2017		For the year ended on 31 March 2016	
	USD	(INR'000)	USD	(INR'000)
A. Cash flow from operating activities				
(Loss) before tax	(3,529)	(237)	(4,160)	(280)
Operating cash flow before working capital changes				
Increase in other current assets	(1,473)	(99)	(1,302)	(88)
Increase in trade payables	4,937	331	5,462	368
Cash generated from operations	(65)	(5)	-	-
Income tax paid (net of refund)	-	-	-	-
Net cash generated from operating activities	(65)	(5)	-	-
B. Effect of exchange rate changes		(1)		5
Net decrease in cash and cash equivalents (A+B)	(65)	(6)	-	5
Add: cash and cash equivalents at the beginning of year	1,371	91	1,371	86
Cash and cash equivalents at the end of the year	1,306	84	1,371	91
<i>Reconciliation of cash and cash equivalents as per the cash flow statement</i>				
Cash and cash equivalents	1,306	84	1,371	91
Bank overdrafts				
Balances per statement of cash flows	1,306	84	1,371	91

Prakash C Bisht
CFO (LSI) & Senior VP (Group Accounts)
Place: Noida
Date: 23 May, 2017

Jubilant Blosys (BVI) Limited

Notes to the financial statements for the year ended 31 March 2017

	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	USD	(INR'000)	USD	(INR'000)	USD	(INR'000)
1. Non-current Investments						
Investment In Subsidiary/Fellow Subsidiaries Companies						
Jubilant Blosys (Singapore) Pte Ltd	1,371,501	88,942	1,371,501	90,862	1,371,501	85,719
137,501 (31 March 2016: 137,501; 1 April 2015 :137,501 share of USD 1 par value)	1,371,501	255,801	1,371,501	90,862	1,371,501	85,719
2. CASH AND CASH EQUIVALENTS						
Cash and cash equivalents						
Balances with banks:						
- On current accounts	1,306	85	1,371	91	1,371	86
	1,306	85	1,371	91	1,371	86
3. OTHER CURRENT ASSETS						
Prepaid expenses	3,096	201	1,623	107	321	20
	3,096	201	1,623	107	321	20

Jubilant Biosys (BVI) Limited

Notes to the financial statements for the year ended 31 March 2017

	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	USD	(INR'000)	USD	(INR'000)	USD	(INR'000)
4. SHARE CAPITAL						
Authorised						
Authorised to issue a maximum of 10,000,000 equity shares with USD 1 par value						
Issued & Subscribed	1,397,501	69,846	1,397,501	69,846	1,397,501	69,846
1,397,501 (31 March 2016; 1,397,501; 1 April 2015; 1,397,501 equity shares with USD 1 par value)						
	1,397,501	69,846	1,397,501	69,846	1,397,501	69,846
Paid up						
1,397,501 (31 March 2016; 1,397,501; 1 April 2015; 1,397,501 equity shares with USD 1 par value)	1,397,501	69,846	1,397,501	69,846	1,397,501	69,846
	1,397,501	69,846	1,397,501	69,846	1,397,501	69,846

Movement in equity share capital

Particulars	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	Number	(INR'000)	Number	(INR'000)	Number	(INR'000)
At the commencement and at the end of the year	1,397,501	69,846	1,397,501	69,846	1,397,501	69,846

Terms and rights attached to equity shares

The Company has only one class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

The details of shareholders holding more than 5% shares in the company

Name of the shareholder	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	Number	% of total shares	Number	% of total shares	Number	% of total share
Jubilant Life Sciences (BVI) Limited	1,397,501	100%	1,397,501	100%	1,397,501	100%

Jubilant Biosys (BVI) Limited

Notes to the financial statements for the year ended 31 March 2017

	As at 31 March 2017		As at 31 March 2016		As at 1 April 2015	
	USD	(INR'000)	USD	(INR'000)	USD	(INR'000)
5. OTHER EQUITY						
Retained earning						
Opening balance	(31,293)	15,530	(27,134)	15,801	(22,877)	16,062
Add: Net loss after tax transferred from Statement of Profit and Loss	(3,529)	(237)	(4,160)	(271)	(4,257)	(261)
Amount available for appropriation	(34,823)	15,293	(31,293)	15,530	(27,134)	15,801
Exchange differences on translation of foreign operations						
Opening balance	-	5,135	-	-	-	-
Addition/(deduction) during the year	-	(1,904)	-	5,135	-	-
At the end of the year	-	3,231	-	5,135	-	-
	(34,823)	18,524	(31,293)	20,665	(27,134)	15,801
6. TRADE PAYABLES						
Trade payables-others	13,224	858	8,287	549	2,826	177
	13,224	858	8,287	549	2,826	177

Jubilant Biosys (BV) Limited

Notes to the financial statements for the year ended 31 March 2017

	For the year ended 31 March 2017		For the year ended 31 March 2016	
	USD	(INR'000)	USD	(INR'000)
7. OTHER EXPENSE				
Legal , professional and consultancy charges	3,464	233	4,150	270
Bank charges	65	4	10	1
	3,529	237	4,160	271